

1. *Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.*
Gabriel M, Nilica B, Kaiser B, **Virgolini Irene**.
J Nucl Med. 2019 Apr;60(4):524-529.
2. *A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.*
Erba PA, Maecke H, Mikolajczak R, Decristoforo C, Zaletel K, Maina-Nock T, Peitl PK, Garnuszek P, Froberg A, Goebel G, de Jong M, Jabrocka-Hybel A, Konijnenberg M, **Virgolini Irene**, Nock B, Lenda-Tracz W, Pawlak D, Rangger C, Trofimiuk-Müldner M, Sowa-Staszczak A, Tomaszuk M, von Guggenberg E, Scarpa L, Hubalewska-Dydejczyk A.
Pol Arch Intern Med. 2018 Dec 21;128(12):791-795.
3. *DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.*
Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, **Virgolini Irene**, von Guggenberg E.
J Nucl Med. 2019 Jul;60(7):1010-1016.
4. *⁶⁸Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with ¹⁸F-DOPA PET/CT.*
Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, **Virgolini Irene**.
Rev Esp Med Nucl Imagen Mol. 2019 Mar - Apr;38(2):94-99.
5. *Do patients consider computer-adaptive measures more appropriate than static questionnaires?*
Gamper EM, Martini C, Petersen MA, **Virgolini Irene**, Holzner B, Giesinger JM.
J Patient Rep Outcomes. 2019 Jan 29;3(1):7.
6. *The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.*
Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, **Virgolini Irene**; WARMTH Thyroid Group. World J Nucl Med. 2019 Apr-Jun;18(2):123-126.
7. *¹⁷⁷Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.*
Edler von Eyben F, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, **Virgolini Irene**, Soydal C, Kulkarni HR, Baum RP.
Oncotarget. 2019 Mar 29;10(25):2451-2461.
8. *University Professor Emeritus Dr. Georg Riccabona.*
Virgolini Irene.
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1594-1595.

9. *⁶⁸Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with ¹⁸F-DOPA PET/CT and ¹²³I-MIBG SPECT/CT.*
Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzi GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, **Virgolini Irene**.
Nucl Med Biol. 2019 Apr;71:47-53.
10. *European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma.*
Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, **Virgolini Irene**, Fanti S, Balogova S, Pandit-Taskar N, Pacak K. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137.
11. *EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT).*
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, **Virgolini Irene**, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544.
12. *The ⁶⁸Ga/¹⁷⁷Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.*
Maffey-Steffan J, Scarpa L, Sviridenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, **Virgolini Irene**.
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):740.
13. *Visualization of malignant infiltration of the thoracic duct on ⁶⁸Ga PSMA-11 PET/CT in a prostate cancer patient with biochemical recurrence.*
Uprimny C, Kroiss AS, Nilica B, di Santo G, **Virgolini Irene**. Eur J Nucl Med Mol Imaging. 2019 Dec 14. doi: 10.1007/s00259-019-04637-5. [Epub ahead of print]
No abstract available.
14. *Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.*
Klingler M, Rangger C, Summer D, Kaeopookum P, Decristoforo C, von Guggenberg E. Pharmaceuticals (Basel). 2019 Jan 15;12(1). pii: E13.
15. *Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.* Kolenc Peitl P, Rangger C, Garnuszek P, Mikolajczak R, Hubalewska-Dydejczyk A, Maina T, Erba P, Decristoforo C. J Labelled Comp Radiopharm. 2019 Aug;62(10):673-683.
16. *Modifying the Siderophore Triacetylfusarinine C for Molecular Imaging of Fungal Infection.*
Kaeopookum P, Summer D, Pfister J, Orasch T, Lechner BE, Petrik M, Novy Z, Matuszczak B, Rangger C, Haas H, Decristoforo C.
Mol Imaging Biol. 2019 Dec;21(6):1097-1106.

17. *Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89.*
Zhai C, He S, Ye Y, Rangger C, Kaeopookum P, Summer D, Haas H, Kremser L, Lindner H, Foster J, Sosabowski J, Decristoforo C.
Biomolecules. 2019 Mar 6;9(3). pii: E91.
18. *On-cartridge preparation and evaluation of ⁶⁸Ga-, ⁸⁹Zr- and ⁶⁴Cu-precursors for cell radiolabelling.*
Socan A, Petrik M, Kolenc Peitl P, Krošelj M, Rangger C, Novy Z, Svajger U, Gmeiner T, Decristoforo C.
Nucl Med Biol. 2019 Apr;71:23-31.
19. *The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397.*
Dietl AM, Misslinger M, Aguiar MM, Ivashov V, Teis D, Pfister J, Decristoforo C, Hermann M, Sullivan SM, Smith LR, Haas H.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00807-19.
20. *Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study.*
Fresacher K, Helbok A, Reiser M, Blass S, Rangger C, Mair C, von Guggenberg E, Decristoforo C, Andreae F, Zimmer A.
Eur J Pharm Sci. 2019 Nov 1;139:105063.
21. *The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?*
Peñuelas I, Vugts DJ, Decristoforo C, Elsinga PH.
EJNMMI Radiopharm Chem. 2019 Jan 11;4(1):2.
22. *US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations.*
Schwarz SW, Decristoforo C.
EJNMMI Radiopharm Chem. 2019 May 22;4(1):10.
23. *Radionuclides: medicinal products or rather starting materials?*
Neels O, Patt M, Decristoforo C.
EJNMMI Radiopharm Chem. 2019 Aug 20;4(1):22.
24. *Comparison of ⁶⁸Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold.*
Kaeopookum P, Petrik M, Summer D, Klinger M, Zhai C, Rangger C, Haubner R, Haas H, Hajdich M, Decristoforo C. Nucl Med Biol. 2019 Nov - Dec;78-79:1-10.
25. *Hybrid Imaging of Aspergillus fumigatus Pulmonary Infection with Fluorescent, ⁶⁸Ga-Labelled Siderophores.*
Pfister J, Summer D, Petrik M, Khoylou M, Lichius A, Kaeopookum P, Kochinke L, Orasch T, Haas H, Decristoforo C.
Biomolecules. 2020 Jan 22;10(2). pii: E168.

26. *Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease.*
Kroiss AS.
Wien Med Wochenschr. 2019 Feb;169(1-2):25-32.
27. *Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.*
De Dosso S, Treglia G, Pascale M, Tamburello A, Santhanam P, Kroiss AS, Pereira Mestre R, Saletti P, Giovanella L.
Endocrine. 2019 Jun;64(3):456-468.